Navigation Links
Catalent Experts to Present Use of Practical Aspects of New Technologies at Upcoming Bioassay Conference

Somerset, N.J. (PRWEB) March 20, 2015

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Dr. Mike Sadick, Senior Manager, Large Molecule Analytical Chemistry, and Dr. Tom Luntz, Group Leader, Cell Based Assays, will both speak at the upcoming CASSS Bioassay 2015 Conference, to be held at the Sheraton Spring Hotel, Silver Spring, MO, on March 23rd – 24th, 2015.

Dr. Sadick’s presentation, on March 23rd at 2.25 p.m., is entitled “Development and Qualification of a Robust and Easily Executable Bioassay using mRNA transcription, assessed with Dual RT-qPCR, as Assay Response,” and will demonstrate the development of a potency bioassay using transcriptional gene regulation. By using a real time quantitative reverse transcription assay, alongside a Taqman® assay chemistry in a duplex format on a cell line, Catalent has been able to develop an assay to assess induction or inhibition of ligand-induced bioactivity with excellent precision, assay range and reproducibility.

Dr. Luntz will present on March 24th, at 9.50 a.m., on the subject of “Bioassay Evolution and Lessons Learned,” and will discuss the development, evolution and validation of bioassays throughout the pathway of drug commercialization. Using practical examples, he will demonstrate how a bioassay has to be appropriate for growing demands, from initially reflecting the mechanism of action of a drug product to becoming suitable to use for future lot release and stability testing.

Dr. Sadick has over twenty five years of experience within the industry, having worked in the research faculty at UCSF Medical Centre, before joining Genentech as a Senior Scientist in the Bioassay Group supporting Pharmaceutical Science efforts (Phases I - III), and latterly as a Research Advisor at Eli Lilly and Company. He joined Aptuit in 2007 and became Senior Manager of Biopharmaceutical Characterization Services when Catalent acquired Aptuit Clinical Trials Supply in 2012.

Dr. Sadick manages the team responsible for transfer, development, validation, and performance of bioassays and the development, validation, and performance of molecular biological approaches, including qPCR and cell engineering. In addition, his group is responsible for transfer, development, validation, and performance of electro-separation techniques, including slab-gel electrophoresis and capillary electrophoresis. Dr. Sadick received his Bachelor’s Degree in Biology from Johns Hopkins University and his Master’s Degree and Ph.D. in Immunology from the University of Washington.

Dr. Luntz has 30 years of technical experience and 10 years within the industry, having worked in the Agricultural Biotechnology Research Unit (ABRU) of Ciba-GEIGY, and in the UNC School of Medicine before joining Catalent in 2005. As Group Leader of the Cell-Based Assay Group, he manages the team responsible for method development, transfer, qualification, and validation of cell-based test procedures, and also quality control testing following those methods. Dr. Luntz received his Bachelor’s Degree in Biology from Lehigh University and his Ph.D in Biochemistry from Texas A&M University.

For more information on the CASSS Bioassays Conference, visit: and to arrange a meeting with either of the Catalent executives, contact Ed Dutton at NEPR: edward(at)nepr(dot)eu

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit

More products. Better treatments. Reliably supplied.™

Read the full story at

Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related medicine news :

1. Catalent Announces New Organization To Speed New Products To Market
2. Catalent Expands European Clinical Packaging Capabilities, Highlighting Growing Industry Need for Specialty Handling
3. Catalent to Present Positive New Toxicology and Production Data On ADCs Generated with the SMARTag™ Technology Platform at World ADC Frankfurt Summit
4. Catalent and SELLAS Sign Exclusive Agreement for Therapeutic Reprofiling of Zolpidem
5. Catalent Applied Drug Delivery Institute Executives Invited to Speak at ‘Partnering For Cures’ Conference
6. Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition
7. Catalent Announces Two Senior Executive Appointments to Support Global Development and Clinical Services Business Growth
8. Catalent and Cingulate Therapeutics Sign Exclusive Agreement for Development of New ADHD Treatments
9. New OptiPact™ Technology Introduced by Catalent
10. Best Practice and Strategies in Risk Mitigation to be Presented by Catalent Expert at Internal Audit Summit
11. Bioavailability and Controlled Release Symposium Announced by Catalent Applied Drug Delivery Institute
Post Your Comments:
(Date:10/13/2017)... , ... October 13, 2017 , ... The American Board ... become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon ... beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon ...
(Date:10/13/2017)... ... 2017 , ... Apple Rehab Shelton Lakes , which specializes in the ... facility as part of a disaster drill on October 3rd. , Apple Rehab participated ... Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid Plan ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- The Rebound mobile app is poised to become a ... of prescription drug addiction. The app empowers users to develop ... down their dosage in a safe, controlled manner while maximizing ... first 100,000 people to sign up will enjoy 3 months ... ...
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
(Date:9/27/2017)... YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... today announced that its MyDario product is expected to appear on The ... when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The Dr. Oz ... The ...
Breaking Medicine Technology: